Tikcro Technologies Reports 2016 Year End and Fourth Quarter Results

TEL AVIV, Israel, March 9, 2017

Aviv Boim, CEO of Tikcro, commented, "We are continuing our strategy to generate blocking antibodies to a handful of targeted domains of immune modulators for cancer treatment. Our approach aims to identify highly selective antibodies targeting desired discontinued epitopes. These efforts are focused on pre-clinical research to identify new immune-modulation antibodies by leveraging a unique immunization approach, which includes the use of proprietary antigens, followed by high throughput screening of derived B-cells. We are implementing this process with several targets and intend to continue to conduct rounds of these studies."

Net loss for the fourth quarter of 2016 was $340,000, or $0.03 per diluted share. As of December 31, 2016, the company reported $7.5 million in cash and cash equivalents.

About Tikcro Technologies:

Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro's website at www.tikcro.com.

Safe Harbor Statement

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the risks related to early stage biotechnology projects, including, but not limited to, obtaining required licenses at reasonable commercial terms, the development, testing, regulatory approval and commercialization of our proposed products, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods.  We undertake no duty to update any forward-looking information.